Trial reportThe American journal of drug and alcohol abuse2012
CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men.
Trial report in The American journal of drug and alcohol abuse, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity.Nutrients · 2023Trial
- Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress.Drug and alcohol dependence · 2017Trial
- Stress system changes associated with marijuana dependence may increase craving for alcohol and cocaine.Human psychopharmacology · 2013Trial
- Impact of Acute and Chronic Cannabis Use on Stress Response Regulation: Challenging the Belief That Cannabis Is an Effective Method for Coping.Frontiers in psychology · 2021Review
- Precipitated Δ9-THC withdrawal reduces motivation for sucrose reinforcement in mice.Pharmacology, biochemistry, and behavior · 2020Article
- Barriers to the wider adoption of medicinalBritish journal of pain · 2020Article
- Effects of Different Stressors Are Modulated by Different Neurobiological Systems: The Role of GABA-A Versus CB1 Receptor Gene Variants in Anxiety and Depression.Frontiers in cellular neuroscience · 2019Article
- An endocannabinoid receptor polymorphism modulates affective processing under stress.Social cognitive and affective neuroscience · 2018Article
- Exercise as an adjunctive treatment for cannabis use disorder.The American journal of drug and alcohol abuse · 2016Review
- Neurobiological Interactions Between Stress and the Endocannabinoid System.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Review
- Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis.Arthritis research & therapy · 2015Review
- Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses.Biology of mood & anxiety disorders · 2013Article
- Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis.Neuroscience · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThe endocannabinoid system modulates the hypothalamic-pituitary-adrenal (HPA) axis, but the effect of cannabinoid type 1 (CB1) receptor antagonism following chronic CB1 receptor stimulation in humans is unknown.
objectivesTo evaluate effects of the CB1 receptor antagonist rimonabant on the HPA axis in cannabis-dependent individuals.
methodsFourteen daily cannabis smokers received increasingly frequent 20 mg oral Δ9-tetrahydrocannabinol (THC) doses (60-120 mg/day) over 8 days to standardize cannabis tolerance. Concurrent with the last THC dose, double-blind placebo or rimonabant (20 or 40 mg) was administered. Cannabinoid, rimonabant, and cortisol plasma concentrations were measured 1.5 hours prior to rimonabant administration and 2.0, 5.5, and 12.5 hours post-dose.
resultsTen participants completed before premature study termination due to rimonabant's withdrawal from development. Five participants received 20 mg, three received 40 mg, and two placebo. There was a significant positive association between rimonabant concentration and change in cortisol concentration from baseline (r = .53, p < .01). There also was a borderline significant association between rimonabant dose and cortisol concentrations when the dose-by-time interaction was included. Four of eight participants receiving rimonabant (none of two receiving placebo) had greater cortisol concentrations 2 hours after dosing (at 11:30) than at 08:00, while normal diurnal variation should have peak concentrations at 08:00.
conclusionRimonabant 20 or 40 mg did not significantly increase plasma cortisol concentrations, consistent with an absence of antagonist-elicited cannabis withdrawal. SCIENTIFIC SIGNIFICANCE: Rimonabant doses >40 mg might elicit cortisol changes, confirming a role for CB1 receptors in modulating the HPA axis in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.